SCHEDULE: Orca Capital AG Discloses 6.2% Stake in Silexion Therapeutics
Beneficial Ownership Disclosure
Orca Capital AG has reported a 6.2% beneficial ownership stake in Silexion Therapeutics Corp, holding 131,250 ordinary shares.
Summary
- Orca Capital AG, a German entity, has disclosed beneficial ownership of 131,250 Ordinary Shares in Silexion Therapeutics Corp.
- This represents 6.2% of Silexion Therapeutics Corp's outstanding Ordinary Shares.
- The ownership percentage is calculated based on 2,123,892 Ordinary Shares outstanding immediately after Silexion's registered offering.
- Orca Capital AG also holds warrants for 262,500 Ordinary Shares, which are subject to a 4.99% beneficial ownership blocker, preventing exercise if it would result in ownership exceeding this threshold.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of Silexion Therapeutics Corp.
Sentiment
Score: 6
Explanation: The filing indicates a significant institutional investment, which is generally viewed positively as a vote of confidence, though it is a passive stake and does not provide operational or financial performance details.
Positives
- Increased institutional ownership by Orca Capital AG, which can signal confidence in Silexion Therapeutics Corp.
- The reporting person explicitly states the acquisition is not for influencing control, suggesting a passive investment.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from Silexion Therapeutics Corp or Orca Capital AG regarding Silexion's future performance.
Industry Context
This filing indicates an institutional investor, Orca Capital AG, has taken a significant passive stake in Silexion Therapeutics Corp. Such disclosures are common in the market and reflect ongoing investment activity, particularly following a company's registered offering.
Stakeholder Impact
- Shareholders: Increased institutional ownership may enhance market confidence and liquidity.
Key Dates
| Date | Description |
|---|---|
| 09/11/2025 | Date of event requiring the filing of this statement, indicating Orca Capital AG's beneficial ownership exceeded 5%. |
| 09/12/2025 | Date of Silexion Therapeutics Corp's Prospectus filing pursuant to Rule 424(b)(4), describing warrant terms. |
| 09/15/2025 | Date of signature for the Schedule 13G filing by Orca Capital AG. |
Keywords
Silexion Therapeutics, Orca Capital AG, Beneficial Ownership, SEC Filing, Schedule 13G, Ordinary Shares, Institutional Investment, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.